



10/605,498

Amendment Dated: August 10, 2005

Reply to Office Action of May 12, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (withdrawn) A method for treatment of a cancer characterized by elevated expression of hsp27 as compared to non-cancerous tissue of the same type in an individual suffering from the cancer, comprising the step of administering to the individual a therapeutic composition effective to reduce the amount of active hsp27 in the cancer cells, wherein said therapeutic composition comprises an oligonucleotide.
2. (withdrawn) The method of claim 1, wherein the therapeutic composition comprises an antisense oligonucleotide that is sequence specific for hsp27.
3. (withdrawn) The method of claim 2, wherein the antisense oligonucleotide has backbone modifications to provide resistance against nuclease digestion *in vivo*.
4. (withdrawn) The method of claim 2, wherein the antisense oligonucleotide has a length of from 12 to 35 nucleotides.
5. (withdrawn) The method of claim 4, wherein the antisense oligonucleotide comprises a consecutive series of bases as set forth in any of Seq. ID No. 1-81.
6. (withdrawn) The method of claim 4, wherein the antisense oligonucleotide comprises a consecutive series of bases as set forth in Seq. ID No. 82.
7. (withdrawn) The method of claim 1, wherein the therapeutic composition comprises an siRNA that is sequence specific for hsp27.
8. (withdrawn) The method of claim 7, wherein the siRNA has backbone modifications to provide resistance against nuclease digestion *in vivo*.
9. (withdrawn) The method of claim 7, wherein the siRNA has a length of from 16 to 49 nucleotides.
10. (withdrawn) The method of claim 9, wherein the siRNA comprises a consecutive series of bases as set forth in any of Seq. ID No. 83-90.
11. (withdrawn) The method of claim 9, wherein the siRNA comprises a

Appln No.: 10/605,498
Amendment Dated: August 10, 2005
Reply to Office Action of May 12, 2005

consecutive series of bases as set forth in Seq. ID No. 84.

12. (withdrawn) The method of claim 1, wherein the cancer is prostate cancer.
13. (withdrawn) The method of claim 1, wherein the cancer is bladder cancer.
14. (currently amended) A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent, and a pharmaceutically acceptable carrier, wherein the therapeutic agent is an oligonucleotide having a sequence complementary to a portion of Seq. ID No. 91.
15. (original) The composition of claim 14, wherein the therapeutic composition comprises an antisense oligonucleotide that is sequence specific for hsp27.
16. (original) The composition of claim 15, wherein the antisense oligonucleotide has backbone modifications to provide resistance against nuclease digestion *in vivo*.
17. (original) The composition of claim 15, wherein the antisense oligonucleotide has a length of from 12 to 35 nucleotides.
18. (withdrawn) The composition of claim 17, wherein the antisense oligonucleotide comprises a consecutive series of bases as set forth in any of Seq. ID No. 1-81.
19. (original) The composition of claim 17, wherein the antisense oligonucleotide comprises a consecutive series of bases as set forth in Seq. ID No. 82.
20. (withdrawn) The composition of claim 14, wherein the therapeutic composition comprises an siRNA that is sequence specific for hsp27.
21. (withdrawn) The composition of claim 20, wherein the siRNA has backbone modifications to provide resistance against nuclease digestion *in vivo*.
22. (withdrawn) The composition of claim 21, wherein the siRNA has a length of from 16 to 49 nucleotides.
23. (withdrawn) The composition of claim 22, wherein the siRNA comprises a consecutive series of bases as set forth in any of Seq. ID No. 83-90.
24. (withdrawn) The composition of claim 22, wherein the siRNA comprises a consecutive series of bases as set forth in Seq. ID No. 84.

Appln No.: 10/605,498
Amendment Dated: August 10, 2005
Reply to Office Action of May 12, 2005

25. (previously presented) The composition of claim 14, wherein the composition is packaged in dosage unit form.

26. (previously presented) The composition of claim 25, wherein the dosage unit form is an injectable solution.

27. (previously presented) The composition of claim 19, wherein the composition is packaged in dosage unit form.

28. (previously presented) The composition of claim 27, wherein the dosage unit form is an injectable solution.